Oncology News | pharmaphorum

News

FibroGen scientist records data manually into a notebook

FibroGen wields axe as pancreatic cancer drug is canned

FibroGen has pulled the plug on its lead drug pamrevlumab after two failed trials in pancreatic cancer and immediately announced plans to shed three-quarters of its workforce.

News

GSK raises forecasts for 2024, but shares slide

GSK posted a healthy 13% increase in second-quarter sales this morning and raised its forecasts for the year on the back of gains for its cancer and HIV drugs, beating market expectations.

News

Close-up image of a melanoma on the skin

BioNTech cancer vaccine hits the spot in melanoma

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma.

News

Boehringer buys oncology player Nerio in $1.3bn deal

Boehringer Ingelheim has bought Nerio Therapeutics, saying that it is adding a programme that – while still in preclinical development – could be a "centrepiece" of its immuno-oncology pipe

News

Image of the word No in gold neon lights

NICE blocks Enhertu use after pricing talks break down

NICE and drugmakers AstraZeneca and Daiichi Sankyo have all expressed their disappointment at being unable to agree on a price for Enhertu that would allow it to be used on the NHS for peop

News

AMPLIFY results dial up Calquence's potential in CLL

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuste

FibroGen wields axe as pancreatic cancer drug is canned

GSK raises forecasts for 2024, but shares slide

BioNTech cancer vaccine hits the spot in melanoma

Boehringer buys oncology player Nerio in $1.3bn deal

NICE blocks Enhertu use after pricing talks break down

AMPLIFY results dial up Calquence's potential in CLL

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks